Risperidone: Clinical Trials

49 trials of Risperidone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

41 completed, 4 unknown, 1 not yet recruiting, 1 recruiting. 49 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 149Completed 41, Unknown 4, Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1
Phase 28Completed 6, Unknown 1, Withdrawn 1

Follow Risperidone: new trials by email Literature Review of Risperidone trials Research Report on Risperidone

Trials (filtered) newest first · largest first

All 49 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Shortened LSD Intervention for Major Depressive Disorder
LSD, Risperidone - Major Depression Moderate, Major Depression Severe
Phase 1Not yet recruitingJohns Hopkins University102026-12-012026-11-03
Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects
Psilocybin (Usona Institute), Risperidone 1 MG, MRI - Depression - Major Depressive Disorder, Anhedonia
Phase 1RecruitingMedical University of Vienna852025-11-012026-03-24
Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders
tDCS or Transcranial Direct Current Stimulation, Risperidone, Sham tDCS - Attention, Visual Perceptual Weakness
Phase 1 / Phase 2CompletedSpanish Foundation for Neurometrics Development1802024-04-012026-09-10
KF2022#3-trial: Effect of Tea and Cola Beverage on Absorption of Risperidone Oral Solution
Risperidone oral solution - Psychosis, Food-drug Interaction
Phase 1CompletedHelsinki University Central Hospital122023-12-082024-12-05
Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia
Oral risperidone; QUAR F1/2, Dose 1 - Gluteal, Oral risperidone; QUAR F1/2, Dose 2 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Gluteal - Schizophrenia
Phase 1CompletedRovi Pharmaceuticals Laboratories582023-09-262025-09-08
A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole) - Schizophrenia
Phase 1CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.192022-11-152024-06-26
A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole) - Schizophrenia
Phase 1CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.312022-06-132024-06-26
Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant
Risperidone - Schizophrenia
Phase 1 / Phase 2CompletedDelpor, Inc.342021-04-012024-12-27
Comparative Bioavailability of Risperidone.
Risperidone ISM® 100 mg, Risperdal 4mg Tablet - Schizophrenia
Phase 1CompletedRovi Pharmaceuticals Laboratories802021-03-092022-01-05
Electrical Brain Stimulation and Pharmacological Treatments in Autism Spectrum Disorder
RisperiDONE 1 MG/ML, transcranial direct current stimulation, Placebo - Autism Spectrum Disorder
Phase 1CompletedThe National Brain Mapping Laboratory (NBML)452020-08-152023-11-07
Symptomatic Therapy for Patients With Huntington's Disease
Haloperidol 2Mg Tab, Risperidone 1Mg Tab, Zoloft 50Mg Tablet - Huntington Disease
Phase 1UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine602020-03-122021-04-02
PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia
RBP-7000 - Schizophrenia
Phase 1CompletedIndivior Inc.442016-02-012017-01-31
Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone
Aripiprazole, Olanzapine, Paliperidone - Immunoassay, Antipsychotic
Phase 1CompletedJanssen Research & Development, LLC812015-11-092025-08-15
Nicotinic Receptors and Schizophrenia
Risperidone plus Placebo, Risperidone plus DMXB-A - Schizophrenia
Phase 1 / Phase 2WithdrawnVA Office of Research and Development2015-08-012017-05-30
Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia
ZX003 (Risperidone-SABER®), Risperdal Consta, Oral Risperidone - Schizophrenia, Schizoaffective Disorder
Phase 1CompletedZogenix, Inc.602015-02-012022-10-31
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation - Psychotic Disorders, Schizophrenia
Phase 1CompletedJanssen Research & Development, LLC3052014-02-012015-10-29
A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone
Placebo, RO5545965, risperidone - Schizophrenia
Phase 1CompletedHoffmann-La Roche322014-01-012016-11-02
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study
Cannabidiol CR, Cannabidiol, Amisulpride - Schizophrenia
Phase 1CompletedCentral Institute of Mental Health, Mannheim742013-01-012018-03-08
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment
Risperidone, Olanzapine, Quetiapine - Schizophrenia
Phase 1 / Phase 2UnknownShanxi Medical University2002013-01-012016-01-08
A Study of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Volunteers
RO5285119, RO5285119 placebo, risperidone - Healthy Volunteer
Phase 1CompletedHoffmann-La Roche242012-11-012016-11-02

Showing 20 of 49. Sign in to see all of them.

Conditions studied

Schizophrenia (21)  ·  Psychotic Disorders (5)  ·  Depression (3)  ·  Autistic Disorder (2)  ·  Bipolar Disorder (2)  ·  Child Development Disorders, Pervasive (2)  ·  Anhedonia (1)  ·  Autism Spectrum Disorder (1)  ·  Cocaine-Related Disorders (1)  ·  Depressive Disorder (1)  ·  Depressive Disorder, Major (1)  ·  Depressive Disorder, Treatment-Resistant (1)  ·  Dyskinesia, Drug-Induced (1)  ·  Fasting (1)  ·  Huntington Disease (1)

Sponsors

Dr. Reddy's Laboratories Limited (4)  ·  Janssen Research & Development, LLC (3)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (3)  ·  Children's Hospital Medical Center, Cincinnati (2)  ·  GlaxoSmithKline (2)  ·  Hoffmann-La Roche (2)  ·  IPCA Laboratories Ltd. (2)  ·  Indivior Inc. (2)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (2)  ·  Rovi Pharmaceuticals Laboratories (2)  ·  Teva Pharmaceuticals USA (2)  ·  Torrent Pharmaceuticals Limited (2)  ·  Calo Psychiatric Center (1)  ·  Central Institute of Mental Health, Mannheim (1)  ·  Corcept Therapeutics (1)

Countries

United States (20)  ·  India (5)  ·  Spain (4)  ·  Belgium (3)  ·  Canada (3)  ·  China (2)  ·  Germany (2)  ·  Argentina (1)  ·  Austria (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Finland (1)  ·  France (1)  ·  Iran (1)  ·  Jordan (1)

Top investigators

Benoit Girard, MD (2)  ·  Dr. Tarang Shah, M.D. (2)  ·  Geatano Morelli, M.D (2)  ·  Alexander Vinks, Pharm.D., Ph.D. (1)  ·  Amalia Lafuente Flo, Pharmacology professor (1)  ·  Anthony Levitt, MD (1)  ·  Barbara O Rothbaum, PHD (1)  ·  Coleman Gross, MD (1)  ·  David Walling, PhD (1)  ·  Dilip V. Jeste, MD (1)

Results publications

PMID 18278987, PMID 22513041, PMID 24519692, PMID 25468234, PMID 27173384, PMID 29625151, PMID 30509308, PMID 33578648, PMID 33658971, PMID 33823927, PMID 35734582, PMID 37445385

NIH funding

2008 (1), 2009 (1), R01MH059101 (1), R44MH094036 (1)